



## ERACoSysMed 1<sup>st</sup> Joint Transnational Call for Proposals for "European Research Projects to demonstrate the feasibility and benefits of systems medicine"

## **CALL TEXT**

Submission deadline for pre-proposals: 30.03.2015

Online access: https://www.eracosysmed.eu/index.php?index=27

For further information please visit <a href="www.eracosysmed.eu">www.eracosysmed.eu</a>

or contact

the Joint Call Secretariat at eracosysmed.jcs@fz-juelich.de

or contact

Dr. Gisela Miczka / Dr. Marc Kirschner

Project Management Jülich
Division Life Science, Health and Technical Colleges (LGF)
Forschungszentrum Jülich GmbH,
52425 Jülich, Germany
phone: +49 2461 61-2716 / -6863

fax: +49 2461-619080

## Content

1. Introduction
2. Aim of the call
3. Application6
3.1 Eligibility6
3.2 Submission of joint proposals
4. Evaluation 8
4.1 Scoring system
4.2 Evaluation criteria for proposals
4.3 Evaluation procedure9
5. Funding
6. Reporting requirements
Annex I - Indicative timetable of the call
Annex II – National/regional contact persons, budget information and regulations

#### 1. Introduction

The overall aim of Systems Medicine research is to provide a modern systems-based approach to medical practice. This will lead to early stage medical intervention resulting in the prevention of many clinical diseases, the reduction in disease severity, and the ability to apply resources strategically and wisely. This approach is fundamentally different from the prevailing practice of classical medicine, which is typically characterized by a reactive approach, whereby intervention only occurs once a disease has already manifested itself. Systems Medicine aims to understand diseases as a complex interplay of many different biological and clinical networks on multiple levels (e.g. cells, tissues, organs and organism) and dimensions, including co-morbidities.

In the past, clinicians have always integrated clinical observations, empirical knowledge and information from medical tests in order to diagnose diseases and treat patients. This is a proven and successful concept. However, the success of this approach is curtailed by the steep increase in the amount of information that needs to be integrated and the sheer size and complexity of large datasets of modern "-omics" technologies and clinical information.

Systems Medicine approaches will allow the integration of functional information from these datasets into both clinical research and medical practice. Not bridging this gap will deny medicine an enormous amount of patient and disease relevant information. In addition, systems medicine offers a systematic and tractable approach that is reproducible, scalable and evolvable. Systems Medicine will provide a new tool to medical researchers and clinicians that will allow clinicians to diagnose and treat patients faster and more effectively and has the potential to develop a new level of Personalized, Participatory, Preventive and Participatory Medicine (P4-medicine) and change the way to catalyze the Delivery of Care to patients.

ERACoSysMed aims to enhance the implementation of Systems Medicine approaches in both clinical research and medical practice throughout Europe and Israel. The challenge of establishing Systems Medicine in Europe (and beyond) will be addressed by developing transnational cooperation between national ministries and funding bodies and a common research funding framework for Systems Medicine.

As such the ERA-NET Cofund complements other European initiatives that can be of relevance for Systems Medicine (e.g. BBMRI<sup>1</sup>, EATRIS<sup>2</sup>, PerMed<sup>3</sup>), the Coordination and Support Action CASyM<sup>4</sup> and other activities in the field of Systems Biology (ERASysAPP<sup>5</sup>, ERASysBio<sup>6</sup>). More specifically, the CASyM roadmap for the implementation of systems medicine across Europe has been the strategic guide to formulate key objectives of ERACoSysMed in that we will specifically focus on areas where a systems approach is needed to address clinical questions, solve clinical problems and to make personalized medicine a reality.

<sup>&</sup>lt;sup>1</sup>www.structuralbiology.eu/resources/organisations/bbmri-biobanking-and-biomolecular-resources-research-infrastructure, <sup>2</sup>www.eatris.eu, <sup>3</sup>www.permed2020.eu, <sup>4</sup>www.casym.eu,

<sup>&</sup>lt;sup>5</sup>www.erasysapp.eu, <sup>6</sup>www.erasysbio.net

Under the umbrella of ERACoSysMed, the following 14 funding organizations have agreed to launch the first joint call for transnational research projects which is co-funded by the EU:

- The Federal Ministry of Education and Research (BMBF), Germany
- The Austrian Science Fund (FWF), Austria
- The Fund for Scientific Research (FNRS), Belgium
- The Research Foundation Flanders (FWO), Belgium, Flanders
- The French National Research Agency (ANR), France
- Science Foundation Ireland (SFI), Ireland
- The Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
- The Italian Ministry of Health (MoH), Italy
- The National Research Fund (FNR), Luxembourg
- The Netherlands Organization for Health Research and Development (ZonMw), The Netherlands
- The Research Council of Norway (RCN), Norway
- The Slovak Academy of Sciences (SAS), Slovakia
- The Ministry of Higher Education, Science and Technology (MIZS), Slovenia
- The National Institute of Health Carlos III (ISCIII), Spain

#### 2. Aim of the call

The call aims to support the development of Proof of Concept projects (demonstrator projects) which will improve our understanding of Systems Medicine and demonstrate the utility of this approach in a clinical setting.

**Demonstrator** projects should demonstrate the translation of Systems Biology approaches into medical research and practice (Proof of Concept).

- Start with an idea or *concept* based on a clearly defined *clinical need*. The implementation of this concept must be achieved within the envisaged duration of the project. This means that while the idea or concept can have a long-term nature, the project must be directed at testing the feasibility of this idea and result in a Proof of Concept.
- Use a *systems medicine approach* in the demonstrating of a proof of concept. This should lead to new paths for personalized prevention, diagnostics and treatment of human diseases
- Integrate biomedical data and computational/mathematical models originating from previous systems biology approaches that can realistically contribute to P4 medicine and the opening of new ways for clinical research delivering better prevention and more efficient and personalized therapies throughout life.

The projects shall indicate technological and methodological feasibility and the clinical, economic and social benefit with respect to defined medical questions.

As a **prerequisite for funding**, applicants need to demonstrate relevant previous work in the field of medical oriented systems biology. Other prerequisites for funding include a high methodological and scientific quality of planned activities (excellence) and the applicants' willingness to work in interdisciplinary teams, including the set-up of harmonized processes for data collection, data management and data sharing to realize a systems medicine approach from the beginning of the project. The required 'critical mass' of resources and know-how must already be available at the time of application. This applies in particular to the availability of relevant data sets (patient data) and patient samples, both well annotated archived samples and collection of new samples sets for proof of concept, as well as the availability of computational/mathematical models/tools.

Each project shall meet the following conditions (expected technical activities)

- Have effective multidisciplinary collaboration of clinical researchers and medical doctors, translational researchers and computational scientists, industrial partners (where possible), and relevant stakeholders from different countries. Each consortium should include at least one clinical (research)/medical group.
- Address a greater understanding of disease complexity, early diagnosis of disease and the re-definition of disease phenotypes which will lead to improved patient stratification.
- Generate new knowledge which enables the integration of biological and clinical data and the creation of new mathematical/computational models that take into

account the nonlinear spatio-temporal behaviour of complex biological systems. The predictive value of these tools must be validated in well characterized clinical cohorts and the clinical potential must be thoroughly investigated.

- Contribute to refining experimental design and prospective clinical data collection in newly set cohorts by mathematical/computational models which will lead to a better understanding of the biological processes which play a fundamental role in complex disease processes and identification of key common underlying mechanisms in diseases.
- Demonstrate the appropriate quality and relevance of available clinical material and the associated clinical data (patient cohorts with comprehensive clinical characterization/annotation). Exploit the prognostic, diagnostic and therapeutic value of newly collected or already existing clinical material and data or, where relevant, appropriate models.
- Define a clear strategy to clinically validate the outcomes of the project, including the validation of the predictions of *in silico* mathematical/computational models that will be developed using experimental and *ad hoc* collected clinical data.
- Provide a concept for data management and data handling protocols according to internationally state of the art standards. Communication, data storage, data/model exchange and data/model sharing should be agreed upon in a common project knowledge management strategy. In cases that involve the sharing of clinical data, consortia applying will have to provide a data management concept that (i) makes clear that the legal and ethical issues of data management are addressed, i.e. that entities slated to send/receive privacy-sensitive clinical data are (or will be) legally allowed to exchange data and (ii) describes the management and handling of clinical data, pseudonymized & anonymized clinical data, as well of non-clinical data.
- Ensure the comprehensive implementation of a Dissemination Strategy towards key target-groups and particularly to patient organizations and policy makers.

## 3. Application

The 1<sup>st</sup> ERACoSysMed joint transnational call which is co-funded by the EU will be coordinated centrally by the Joint Call Secretariat (JCS) and will be conducted simultaneously by the funding organizations in their respective countries.

The call will be implemented through a two-step evaluation procedure including submission and evaluation of pre-proposals and full proposals. Applicants must refer and comply with the specific regulations of the national funding organizations (see Annex II). Therefore applicants are strongly encouraged to contact their respective contact person for any queries related to their national regulations.

## 3.1 Eligibility

Each funding organization will check the eligibility of their national applicants, and the JCS will check the eligibility of the applications.

Applicants are strongly advised to contact their corresponding national/regional representative and confirm eligibility with their respective funding organizations in advance of submitting an application (see Annex II).

**Proposals** must meet the following eligibility criteria:

- Proposals must be submitted before the application deadlines. Applicants are strongly encouraged to follow the guidelines for applicants under (https://www.eracosysmed.eu/preview.php?index=15).
- Proposals must be submitted electronically in the submission tool by the coordinator of the project.
- Proposals must be written in English.
- Proposals must follow the templates provided under (https://www.eracosysmed.eu/preview.php?index=15).
- Only projects with project duration of up to three years will be funded.
- Only transnational research projects will be funded. Each consortium submitting a proposal must involve a minimum of three and a maximum of six eligible partners from three different countries participating in the call (not more than two eligible partners per country/funding agency).
- Non-eligible partners that will not receive funding from the 1<sup>st</sup> ERACoSysMed joint transnational call (JTC-1) may participate in a consortium, providing their own money. The maximum number of partners should not exceed 8 (to avoid an imbalance, a minimum of 50% of all partners must be eligible). Not more than two eligible research groups from the same partner country participating in the call will be accepted.

The consortium members must nominate one partner to act as coordinator. The coordinator must be eligible and from a country from which funding organizations participate in the call. In case of awarding of a grant, the individual research groups will be funded by the individual funding organization of their country/region participating in the 1<sup>st</sup> ERACoSysMed joint transnational call.

**IMPORTANT: Full proposals** will be accepted only from consortia explicitly invited by the JCS to submit them

#### 3.2 Submission of joint proposals

In both steps (pre-proposals and full proposals), one joint proposal should be prepared by the partners of a transnational consortium. Only pre-proposals and full proposals which duly follow the templates provided in the "Guidelines for applicants" and on the website and submitted in the ERACoSysMed submission tool in time will be accepted.

Submission deadline for pre-proposals is 30.03.2015 at 17:00 CET.

The result of the evaluation of the pre-proposals will be communicated to the coordinators by the JCS by mid May 2015. The coordinators of successful pre-proposals will be invited to submit a full proposal. Submission deadline for full proposals is **30.06.2015** at **17:00** CET.

Information on how to submit pre-proposals and full proposals electronically is available on the ERACoSysMed website (www.eracosysmed.eu) and in the "Guidelines for applicants". Pre-proposal and full proposal templates are available on the ERACoSysMed website.

A summary of the deadlines of the call can be found in Annex I.

IMPORTANT: Applicants should take note of individual national/regional rules. For applicants from some countries/regions it might be necessary to submit additional documents and/or other information directly to the country/regional funding organizations. Therefore, applicants are strongly advised to check this issue with their national/regional funding organizations for more details (see Annex II).

#### 4. Evaluation

All proposals will be subject to a peer-review and a joint decision process of the funding organizations participating in the call.

#### 4.1 Scoring system

Pre-proposals and full proposals will be assessed according to specific evaluation criteria given below. A scoring system from 0 to 5 will be used to evaluate a proposal's performance with respect to the different evaluation criteria, whereas the meaning of the scores is:

- 0 The proposal fails to address the criterion or cannot be assessed due to missing or incomplete information.
- 1 Poor. The criterion is inadequately addressed, or there are serious inherent weaknesses.
- 2 Fair. The proposal broadly addresses the criterion, but there are significant weaknesses.
- 3 Good. The proposal addresses the criterion well, but a number of shortcomings are present.
- 4 Very Good. The proposal addresses the criterion very well, but a small number of shortcomings are present.
- 5 Excellent. The proposal successfully addresses all relevant aspects of the criterion. Any shortcomings are minor.

#### **4.2 Evaluation criteria for proposals**

The experts will assess the pre-proposals as well as full proposals based on the following criteria:

#### 1) Excellence

- sound rationale and research hypothesis based on a clinical need;

- clearly defined idea or concept
- use of an innovative and suitable approach for applying Systems Medicine
- feasible testing of the concept during the course of the project
- expected progression beyond the current state-of-the-art

## 2) Impact

- meets the aims of the call (the general advancement, implementation and consolidation of the establishment of Systems Medicine approaches tailored for medical research and/or the clinic) and clearly contributes to the increasing of European competitiveness by leveraging —as a substantial added value- on existing investments in Systems Medicine;
- the potential of results that lead to future clinical, public health and/or other socioeconomic relevant applications and benefits with a clear evidence that Systems Medicine do represent an improvement over established practice;
- suggest new paths for clinical research aiming at delivering better prevention and more efficient and personalized therapies throughout life;
- support the European Policy for the development of personalized medicine

#### 3) Quality and efficiency of implementation

- balance of the partnership, transnational added value and quality of the consortium
- adequate use of data management;
- allocation and justification of resources;
- adequate project management, stating task allocation, deliverables, milestones and using a Gantt chart

## 4.3 Evaluation procedure

Pre- and full proposals will be evaluated according to the evaluation criteria above. Evaluations will be carried out by the independent evaluator experts.

Each pre-proposal will be remotely evaluated by three evaluator experts who will produce individual evaluation reports according to the evaluation criteria. Based on the scores in the written reports a ranking list will be set up. Based on the ranking list the CSC will decide which pre-proposals will be invited to submit full proposals. If necessary, the number of proposals that are invited to submit full proposals may be limited to a funding total of two or three times that of the available budget of the call.

Each full proposal will be remotely evaluated by at least three evaluator experts who will produce individual evaluation reports according to the evaluation criteria.

#### Rebuttal step

The evaluation process foresees a rebuttal phase for full proposals to provide applicants with the opportunity to reply to issues raised by the experts in the remote phase. All remote reviews will be made available through the submission system for the corresponding project coordinator without revealing the identity of the reviewers. Project coordinators may comment on possible factual errors or misunderstandings and reply the evaluators' questions after consulting the consortium. However, issues which are not related to evaluators' comments or questions cannot be addressed and the work plan cannot be modified at this stage.

The applicants will have up to one week for the optional response to the evaluators' comments.

#### **Panel meeting**

A consensus meeting will be held in which the experts will discuss each full proposal and determine the final scores. Based on these scores a ranking list will be established as the outcome of the evaluation

Subsequently, the funding organizations will issue a selection list of projects to be funded following the order of the ranking list.

## 5. Funding

An earmarked budget of approximately EUR 12 Mio is available for these projects. Indicative budgets per participating funding organization are indicated in Annex II under National budget commitment.

#### **Consortium Agreement**

The coordinator of a successful research project consortium is responsible for the preparation and negation of the consortium agreement (CA) among the participating partners (addressing the issues listed in the "Guidelines for Applicants"). Any intellectual property issues arising will be dealt with through this agreement thereby ensuring that these are not in conflict with the regulations of the programme owners. Partners of the project are strongly encouraged to sign the CA before the official project start date, and in any case the CA has to be signed no later than six months after the official project start date. Please note that national regulations may apply concerning the requirement for a CA. On request, the Consortium Agreement must be made available to the JCS or national funding organizations, together with any other information required by national regulations.

Support for the preparation of a consortium agreement can be found on the DESCA webpage (http://www.desca-2020.eu/).

## 6. Reporting requirements

#### Publication of funded project abstracts

Abstracts of the projects selected for funding will be published on the ERACoSysMed website.

#### Reporting on national level

Individual research groups will be monitored by their respective national funding organization. Therefore, the individual research groups must report to their respective national funding organization according to the national rules.

#### Reporting on the level of ERACoSysMed

In addition to the national reporting obligations, the project coordinator shall submit on behalf of the consortium annual and final progress reports in English to the JCS. Templates for the reports will be provided by the JCS. These joint reports will be assessed by the JCS. The coordinators and/or principal investigators may be asked to present the results of the funded projects at mid-term and final status seminars.

An executive non-confidential summary of reports will be published on the ERACoSysMed homepage. Any publications resulting from the funded projects must acknowledge the respective national funding organizations and the ERACoSysMed. An electronic copy of such publications must be sent to the JCS.

#### Annex I - Indicative timetable of the call

16.02.2015	Publication of the call
30.03.2015	Submission deadline for pre-proposals
Mid May 2015	Communication of the results of the pre-proposal assessment and invitation for full proposals
30.06.2015	Submission deadline for full proposals
late October 2015	Communication of the results of the full proposal assessment
Early 2016	First projects start

# Annex II - National/regional contact persons, budget information and regulations

Country		Germany	
Funding organization		BMBF	
Contact person		Dr. G. Miczka	Dr. M. Kirschner
1		Tel: +49-2461-612716	Tel: 49-2461-616863
		E-mail: g.miczka@fz-	E-Mail: m.kirschner@fz-
		juelich.de	juelich.de
National budget	t commitment	3,98	
(Mio €)			
Maximum fi	unding per		
participant or	1		
number of research	ch groups to be		
funded	T		
	Academia	Yes	
	Hospitals	Yes	
Elizibilitza C	Industry	Yes	,
Eligibility of			artner in a proposal, must be
applicants			I must be well established in
			oratories, employees, etc. The add benefit to the national
		economy.	idd benefit to the national
Eligible costs			consumables, equipment and
Engiole costs		subcontracts according	
		Overheads are eligible costs	
Additional docu	iments to be		c submission of pre-proposals
submitted			contact Project Management
Submitted		Jülich and may have to subr	
		<ul> <li>Kopie des Antrags</li> </ul>	
		1	3 oder vorläufige Bilanz 2012
			ingung des Eigenanteils
		Aktuelle BWA	
		<ul> <li>Liquiditätsplanung f</li> </ul>	r die Laufzeit des
		vorgeschlagenen Pro	
		In case of positive funding r	ecommendation, German
			formal national application via
		the electronic application sy	•
		(https://foerderportal.bund.d	le/easy)
Earliest project start date		Early 2016	
Further guidance			ne follow-up and reporting of
			are regulated according to
		`	ebenbestimmungen), BNBest
		(Besondere Nebenbestimmungen) and NKBF 98	
		(Nebenbestimmungen für Zuwendungen auf Kostenbasis des Bundesministeriums für Bildung und Forschung an	
			verblichen Wirtschaft für
		Forschungs- und Entwicklung	
		1 015011d11g5- und Entwicklu	1150 (011140011).

Country		Austria
Funding organization		FWF
Contact person		Dr. Markus Kubicek
		Tel: +43-1-505 67 40-8202
		E-Mail: markus.kubicek@fwf.ac.at
National budget	t commitment	0,5
(Mio €)	1:	The FWF and instant for the of the projects Circum the
Maximum fu participant or	anding per anticipated	The FWF anticipates funding of two projects. Given the maximum commitment of $\in$ 0,5 Mio, individual proposals
number of research		should be in the range of approx. € 250.000 and should
funded	on Bromps to ot	definitely not exceed the maximum commitment of $\in 0.5$
		Mio.
	Academia	YES
		Applications may only be submitted by individual natural
		persons. Eligibility criteria will strictly follow the general
		Funding Guidelines  (http://www.fv.fac.at/do/forgehungsfoorderung/ontroastell
		(http://www.fwf.ac.at/de/forschungsfoerderung/antragstell ung/einzelprojekte/)
	Hospitals	YES
	1100p10010	Applications may only be submitted by individual natural
Eligibility of		persons. Eligibility criteria will strictly follow the general
applicants		Funding Guidelines
		(http://www.fwf.ac.at/de/forschungsfoerderung/antragstell
	T 1 4	ung/einzelprojekte/)
	Industry	YES Applications may only be submitted by individual natural
		persons. Eligibility criteria will strictly follow the general
		Funding Guidelines
		(http://www.fwf.ac.at/de/forschungsfoerderung/antragstell
		ung/einzelprojekte/)
Eligible costs		For scientists funded by the FWF, the funding is limited to
		"project-specific costs, i.e. personnel and non-personnel
		costs that are essential to carry out the project and that go
		beyond the resources made available from the research institution's infrastructure, according to the general FWF
		Funding Guidelines published at
		http://www.fwf.ac.at/de/forschungsfoerderung/antragstellu
		ng/einzelprojekte/.
		The FWF does not finance infrastructure or basic
		equipment at research institutions. Overheads may not be
		requested. Subcontracts must be well justified, i.e. must
		represent the only or the most economical way to have the work performed, please contact the FWF directly for
		clarification of individual cases
Additional docu	iments to be	The following forms and project specific data must be sent
submitted submitted		both on paper and electronically (upon notification by the
		FWF secretariat):
		1) FWF forms (completed, signed and stamped as
		appropriate) including Application Form, Programme
		Specific Data, Attachment Co-Author, Itemization of
		requested funding, and, if applicable, National Research

	Partner.
	2) Additional form international cooperation: should be
	completed for each additional partner in the consortium.
	3) If items of equipment are requested (costs above €1,500
	incl. VAT), Itemization form Equipment must be
	completed for each item requested
	4) One-page summary in English and in German (largely
	for PR work)
	All forms are found under:
	http://www.fwf.ac.at/en/research-
	funding/application/international-programmes/joint-
	projects-era-nets/
Earliest project start date	January 2016
Further guidance	Applications must fulfill the requirements of the FWF
	application guidelines published at
	http://www.fwf.ac.at/de/forschungsfoerderung/antragstellu
	ng/einzelprojekte/.
	Please contact the national contact person for further
	information.

Country		Belgium
Funding organization	on	FNRS
Contact person		Dr. Arnaud Goolaerts
_		Mrs. Freia Van Hee
		Tel: +32 2 504 93 09
		E-Mail: <u>Arnaud.goolaerts@frs-fnrs.be</u> ;
		Freia.vanhee@frs-fnrs.be
National budget	commitment	0,2
(Mio €)		
Maximum funding		The FNRS anticipates to fund one project. Given the
or anticipated num		maximum commitment of € 0,2 mio, individual proposals
groups to be funded		not exceed the maximum commitment of € 0,2 mio.
	Academia	YES
		Applications may only be submitted by individual natural
		persons. Eligibility criteria will strictly follow the rules
Eligibility of		and regulations of FNRS:
applicants		http://www.ncp.fnrs.be/index.php/appels/era-nets
	Hospitals	Academic hospitals only under certain conditions, see:
		http://www.ncp.fnrs.be/index.php/appels/era-nets
	Industry	NO
Eligible costs		Eligible cost items include personnel, equipment and
		russing costs within the limits stipulated in the rules and
		regulations for this call:
		http://www.ncp.fnrs.be/index.php/appels/era-nets
Additional docum	nents to be	Funded researchers have to provide additional
submitted		administrative information to FNRS.
Earliest project start date		One month after the final funding decision of the Call
		Steering Committee.
Further guidance		Please contact the national contact person for further
		information

Country		Belgium
Funding organization		FWO
Contact person		Dr. Olivier Boehme
_		+32 (0)2 550 15 45
		eranet@fwo.be
National budget	commitment	0,2
(Mio €)		
Maximum funding	per participant	1 project at maximum 200.000 euro
or anticipated num	ber of research	
groups to be funded	d	
Eligibility of	Academia	Yes
Eligibility of	Hospitals	No
applicants	Industry	No
Eligible costs		Staff, consumables and equipment as specified in
		Articles 17-22 of the FWO Regulations for Research
		Projects (http://www.fwo.be/en/fellowships-
		funding/research-projects/research-project/regulations-
		for-research-projects/)
Restriction to project duration		3 years
Additional documents to be		None
submitted		
Earliest project start date		Variable
Further guidance		eranet@fwo.be

Country		France
Funding organization	on	ANR
Contact person		Dr. Serena Battaglia
		Tel: +33-178098014
		E-mail: serena.battaglia@agencerecherche.fr
		Dr. Daria Julkowska
		Tél: +33-178098078
		E-mail: daria.julkowska@agencerecherche.fr
National budget	commitment	2
(Mio €)		
Maximum funding per participant		The ANR has a maximum funding per partner for this
or anticipated number of research		call: each research team can be funded with a maximum
groups to be funded	d	amount of 250 000 €. Minimum amount per partner:
		15 000 €"
Eligibility of	Academia	Yes
applicants	Hospitals	Yes
applicants	Industry	Yes
Eligible costs		Personnel, Consumables, Subcontracts (subcontracting
		costs of max 50% of requested budget per partner),
		Small Equipment, Travel
		Maximum rate of support 100% of additional costs for
		partners from academia and hospitals, 45% of total costs
		for SMEs and 30% of total costs for larger companies

Additional documents	to	be	None
submitted			
Earliest project start date			December 2015
Further guidance			The online specific annex document for research groups
			applying to this call for funding in France:
			http://www.agence-nationale-
			recherche.fr/ERACoSysMed-2015

Country		Ireland
Funding organization		SFI
Contact person		Dr Kevin Walsh
1		Tel: +353-1-6073139
		E-mail: kevin.walsh@sfi.ie
National budget	commitment	0,58
(Mio €)	• • • • • • • • • • • • • • • • • • • •	
Maximum funding	per participant	Funding sought cannot be in excess of the national
or anticipated num		budget commitment. Applicants need to fully justify
groups to be funded		their grant budget.
	Academia	YES
		- The investigator(s) from Ireland must be
		from a recognized host institution.
		- The investigator must hold a PhD, MD or
		equivalent.
		- The PI named on the award must:
		<ul> <li>hold a post (permanent or a contract that</li> </ul>
		covers the duration of the award) in a
		recognised research institution in the
		Republic of Ireland (the "Host
		Institution") as an independent
		investigator, <b>OR</b>
		• be a contract researcher recognised by the
		Host institution as an independent
		investigator who will have a dedicated
Eligibility of		office and research space for the duration
applicants		of award, for which he/she will be fully
арричания		responsible, <b>OR</b>
		<ul> <li>be an individual who will be recognised</li> </ul>
		by the Host Institution upon receipt of the
		award as a contract researcher as defined
		above. The Principal Investigator does
		not necessarily need to be employed by
		the Host Institution at the time of the
		application submission.
		- The PI must have demonstrated research
		independence through securing at least one peer-
		reviewed, independent research grant as a
		Principal Investigator or as Co-Investigator and
		be a senior author (first, last or corresponding or
		· · · · · · · · · · · · · · · · · · ·
		in those fields where alphabetic order authorship
		is the norm, joint author) in peer-reviewed

		scientific journals.  The PI cannot request a salary.  Any named co-applicants cannot request their own salary.
	Hospitals	NO
	Industry	NO
Eligible costs		<ul> <li>Salary-related costs</li> <li>Small equipment costs</li> <li>Travel</li> <li>Direct running costs</li> <li>Dissemination and knowledge exchange costs</li> <li>Overheads.</li> </ul>
Additional docur submitted	nents to be	
Earliest project star	t date	December 2015
Further guidance		Please also refer to the "Science Foundation Ireland: Grants and Awards: Grant Terms & Conditions" and also the SFI grant application budget policy.

Country		Israel
Funding organization	tion	CSO-MOH
Contact person		Dr. Ahmi Ben-Yehudah
		Tel: +972-2-5082161
		E-mail: ahmi.by@moh.health.gov.il
National budge	t commitment	0,20
(Mio €)		
Maximum fundin	g per participant	CSO-MOH intends to finance 2 projects with a maximum
or anticipated nur	mber of research	funding of 100K€. If two groups apply for the same
groups to be funde	ed	project – a total of 100K will be divided between the
		groups.
Eligibility of	Academia	YES
applicants	Hospitals	YES
	Industry	NO
Eligible costs		No salaries for applicants
		No heavy equipment
	uments to be	1)-Prior to deadline, a short summary should be
submitted		submitted to CSO-MOH by email. with Research
		authority CC'ed
		summary should include:
		Project name and acronym, project partners and
		affiliations, requested budget and Description of work
		with emphasis on Israeli partner. The total length should
		not exceed 1 page,
		2)-National application forms will be filled after funding
		recommendation
Earliest project start date		01.01.2016
Further guidance		http://www.health.gov.il/Subjects/research/Pages/Researc
		<u>h-Foundation.aspx</u>

Any other issue?	PI can have only one funded project from CSO-MOH at
	any given time

Country		Italy
Funding organization		Ministero Della Salute
Contact person		Dr. Gaetano Guglielmi (g.guglielmi@sanita.it)
		Head office 3 (Health Research, IRCCS)
		Direzione Generale della ricerca sanitaria e biomedica e
		della vigilanza sugli enti
		Viale Giorgio Ribotta, 5
		00144 Roma
		Telefono: 0659943686
N	•.	Fax: 0659943128
National budget (Mio €)	commitment	0,5
Maximum funding		The Ministry of Health intends to finance 3 to 4 projects.
or anticipated num		Maximum funding for grant awarded to a project partner
groups to be funded		about 0.20 M€
Eligibility of	Academia	NO
applicants	Hospitals	Only NHS Institution
- 1 -	Industry	NO
Eligible costs		Only costs generated during the lifetime of the project
		can be eligible.
		Personnel (only ad hoc contracts/consultants/fellowship,
		max 50% of the requested fund); travel costs and
		subsistence allowances (max 10% of the requested fund); equipment (rent/leasing only), consumables,
		dissemination of results (publications,
		meetings/workshops etc.) (max 1% of the requested
		fund); data handling and analysis; overhead (maximum
		10% of the requested fund). (All according to national
		regulations).
		Travel expenses and subsistence allowances associated
		with training activities linked to the project.
Additional docum	nents to be	In order to expedite the eligibility check process, the
submitted		Ministry of Health will grant an eligibility clearance to
		the applicants prior to the submission of the pre-
		proposals. To this end, it is mandatory that the applicants
		fill out and return a pre-eligibility check form trough
		IRCCS Scientific Directorate or Regional Research
		Office using WFR System, before submitting their pre-
		proposals to the Joint Call Secretariat. It is strongly
		recommended that the form, completed and duly signed,
		is returned at least 10 working days before the pre-
		proposal submission deadline. Applicants will be sent a
		written notification of their eligibility status.
Earliest project start date		1.10.2015
Further guidance		Further information on the rules of the Ministry of
		Health can be found at www.salute.gov.it, on the
		website page dedicated to the yearly national calls

	(Bando ricerca finalizzata e giovani ricercatori), or
	requested to the national contact persons.
Any other issue?	After the joint ERACoSysMed-JTC 2015 peer review
	has been completed and the final (scientific) ranking list
	has been performed and endorsed by the Call Steering
	Committee, the Ministry of Health will invite the
	principal investigators of the projects approved for
	funding to enter the formal national negotiations
	(according to national regulations) and subscription of a
	specific agreement.
	Submission of annual scientific and financial reports at
	the national level will be required according to the rules
	of the Ministry of Health. The Ministry of Health
	informs that according to the National Financial Law,
	the budget allocated to the project might be sent only
	after the "PERENZIONE" procedures will be
	completed, and that NHS Institution need to ensure
	financial support until the money transfer will be
	completed.

Country		Luxembourg
Funding organization		FNR
Contact person		Frank Glod
_		frank.glod@fnr.lu
		Tel: +352-26 19 25-33
		Fax: + 352-26 19 25-35
National budget	commitment	0,35
(Mio €)		
Maximum funding	per participant	1-2
or anticipated num	ber of research	
groups to be funded		
Eligibility of	Academia	Eligibility of applicants
applicants	Hospitals	
applicants	Industry	
Eligible costs		Salary-related costs
		Small equipment costs
		Travel
		Direct running and issemination and knowledge
		exchange costs
		Overheads
Additional documents to be		A summary of the submitted proposal will have to
submitted		submitted also via the FNR grant management system
Earliest project start date		
Further guidance		Applicants should contact the National Call Secretariat
		before application of a proposal
Any other issue?		

Country	The Netherlands
Funding organization	ZonMw

Contact person		Dr. Rob Diemel Tel: +31 70 349 52 52
		E-mail: diemel@zonmw.nl
National budget	commitment	1 M€
(Mio €)		
Maximum funding		Under this call ZonMw aims to fund the Dutch
or anticipated num groups to be funded		partner(s) of four research projects. Per project, maximally k€ 250 can be requested from ZonMw. This
groups to be funded	J	budget must include a reserved budget of minimally 5 k€
		for data management (incl. travel and subsistence for the
		project data management representative / PAL).
	Academia	Eligibility of applicants
Eligibility of	Hospitals	Yes, when in line with Grant Terms and Conditions. See
applicants		www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/
wpprounts	Industry	Yes, but industry is not allowed to apply for ZonMw
E1: 11 4		budget in this call
Eligible costs		The resources provided may be used to pay for academic staff (e.g. postdoc, programmer).
		starr (e.g. postdoc, programmer).
		Part of the budget may also be used for:
		- consumales and small equipment required specifically
		for the project.
		- travel and subsistence to visit labs of consortium
		partners, to visit conferences and to attend training
		courses necessary for conducting the research of the
		project  discomination knowledge evaluate and
		- dissemination, knowledge exchange and implementation
Additional documents to be		Implementation
submitted		
Earliest project start date		
Further guidance		Applicants must contact the National Call Secretariat
		before application of a proposal!

Country		Norway
Funding organization	on	RCN
Contact person		Ina K. Dahlsveen
		Tel: +47 40922299
		E-mail: ikd@rcn.no
National budget	commitment	1,42
(Mio €)		
Maximum funding	per participant	679 000 EUR (5 mill NOK)
or anticipated num	ber of research	
groups to be funded		
Elicibility of	Academia	Eligibility of applicants
Eligibility of	Hospitals	
applicants	Industry	
Eligible costs		Universities and research organisations may receive
		funding according to the rules of Researcher projects
		(Forskerprosjekt) of RCN. In these cases up to 100% of

	total eligible costs may be funded. Companies and commercial entities may receive funding according to the rules of Innovation Project for the Industrial Sector (Innovasjonsprosjekter i næringslivet) of RCN. In these cases up to 50% of total eligible costs may be funded.
Additional documents to be submitted	
Earliest project start date	December 2015
Further guidance	
Any other issue?	The Research Council of Norway (RCN) participates through the national program Biotechnology for Innovation (BIOTEK2021) in all call topics. RCN does not require a national application, but it should be clear from the common application what role the Norwegian partners would have and the size of their budget.

Country		Slovakia
Funding organization		Slovak Academy of Sciences (SAS)
Contact person		Ms Katarina BIBOVA
_		International Cooperation Cepartment
		Stefanikova 49
		814 38 Bratislava
		Slovak Republik
		Tel: +421 2 5751 0136
		E-mail: bibova@up.upsav.sk
		Dr. Jan BARANCIK
		Head of International Cooperation of SAS
		barancik@up.upsav.sk
National budge	et commitment	0,24 Mio. €
(Mio €)		
	ding per participant	1-2
	number of research	
groups to be fu		
Eligibility of	Academia	Eligibility of applicants
applicants	Hospitals	
- 1 1	Industry	
Eligible costs		Direct costs (DC): Personnel (max. 15% of DC),
		Consumables, Equipment (max. 40% of DC)
		and Travel costs
		Indirect costs (IC - overheads): max. 20 % of DC.
		Total eligible costs = DC + IC
		Training costs shall not be
		defined as a separate category,
		but included in other costs items
Restriction to project duration		Max 3 years
Additional documents to be		National phase: Submission of the proposal at the
submitted		national level will be required in parallel to the
		international evaluation. The submission will be carried

	out once the international evaluation and the ranking list
	have been performed and endorsed by the
	ERACoSysMed Call Steering Committee (CSC) and the
	Slovak project partner has been informed by the project
	consortium coordinator and invited by SAS to submit the
	proposal to it (Formular MVTS). The Presidium of SAS
	makes the final decision for funding of selected projects
	Further guidance: • Web site: http://www.sav.sk/
	• 133 Act of February 19, 2002 on the Slovak
	Academy of Sciences,
	<ul> <li>Financial rules for awarding SAS grants for</li> </ul>
	research projects in frame of ERA.Net
	Programme for research institutes of SAS
	http://www.sav.sk/index.php?lang=sk&charset=&doc=se
	rvices-news&source_no=25&news_no=5570
	<ul> <li>Principles of allocation of funds for the institutes of</li> </ul>
	SAS to support projects in the field of international
	scientific cooperation
Any other issue?	

Country		Slovenia
Funding organization		Ministry of Education, Science and Sport (MIZS)
Contact person		Mr. Luka Živić
		Science Directorate (MIZS)
		Masarykova 16, 1000 Ljubljana
		T: + 386 1 478 47 56
		Email: luka.zivic@gov.si
National budget	commitment	178.000,00 EUR
(Mio €)		
Maximum funding	per participant	1-2 research groups
or anticipated num		The total requested funding for a Slovenian partner in a
groups to be funded		consortium should not exceed 89.000,00 EUR.
Eligibility of	Academia	Eligibility of applicants
applicants	Hospitals	
applicants	Industry	
Eligible costs		MIZS will fund eligible costs of Slovenian partners
		participating in successful transnational projects,
		recommended for funding in accordance with the
		Decree on criteria and standards for allocating resources
		for the implementation of the National Research and
		Development Program (Official Gazette of the Republic
		of Slovenia No. 103/11, 56/12 and 15/14):
		https://www.arrs.gov.si/sl/akti/ured-normstand-rd-
		marec14.asp.
		Funding is subject to the availability of national funds
		and will be conducted in accordance with the
		Community Framework for State Aid for Research and
		Development and Innovation (2006/C 323/01):
		http://eur-lex.europa.eu/legal-

				content/EN/ALL/?uri=CELEX:52006XC1230(01).
Additional	documents	to	be	The Slovenian applicants participating in the call will be
submitted				required to send a national application form (including
				description of work and budget) in parallel to submitting
				the proposal to ERACoSysMed call. Further instructions
				how to proceed will be published on the MIZS website:
				http://www.mizs.gov.si/si/javne objave in razpisi/okro
				znice/arhiv okroznic/okroznice razpisi in javna naroc
				ila/javni_razpisi/.
Earliest proj	ect start date			1 January 2016
Further guid	lance			Applicants are strongly advised to contact the Slovenian
				National Contact Person Mr. Luka Živić before
				preparing proposals for application.
Any other is	sue			

Country	Chain
Country  Eunding organization	Spain National Institute of Health Carlos III (ISCIII)
Funding organization	Carme De Andres Sanchis
Contact person	
	Building 6
	Monforte de Lemos 3 & 5
	2829 Madrid - Spain
	Tel.: +34-918222545
	Email: cdandres@isciii.es
National budget commitment (Mio €)	0,5
Maximum funding per participant	3-5 research groups
or anticipated number of research groups to be funded	<ul> <li>Maximum € 100,000.00 per project partner. Should there be 2 Spanish partners funded by ISCIII in the same proposal, a maximum of € 150,000.00 may be awarded.</li> <li>Maximum € 150,000.00 per consortium coordinator. Should there be 2 Spanish partners funded by ISCIII in the same proposal, a maximum of € 200,000.00 may be awarded</li> <li>Funding by ISCIII is subject to the approval of the relevant annual appropriations by the Spanish</li> </ul>
A 1 ·	Parliament
Academia	TT 1.1
Hospitals	Hospitals
	• Primary health care or public health settings (from
	the National Health Service) with legal address in
	Spain (for further information please check Spanish
Eligibility of	Act 50/ 2002, December 26th).
applicants	• Certified Health Research Institutes in accordance
	with the Royal Decree 339/2004 (only if the Spanish
	applicant is the consortium coordinator).
	• CIBERs (only if the Spanish applicant is the
	consortium coordinator).
Industry	

Eligibility of PIs and research members  Eligible costs	<ul> <li>Only one application can be submitted per Spanish partner: additional submissions will be rejected.</li> <li>PI must be a senior researcher and have a contractual relationship with an eligible organisation.</li> <li>Research team members must have a contractual relationship/fellowship with an eligible organisation.</li> <li>Excluded personnel as Principal Investigator (PI):</li> <li>Those undergoing a postgraduate training in Health Specialisation.</li> <li>Those currently undergoing research training (e.g. PhD students, or "Rio Hortega Programme").</li> <li>Research personnel contracted by a RETICS or a CONSOLIDER.</li> <li>Those undergoing Post-doctoral training (e.g. "Sara Borrell" or "Juan de la Cierva" contracts).</li> <li>Only expenses and invoices charged during the lifespan of the awarded grant will be accepted.</li> <li>Personnel costs Hiring additional full-time or part-time technical personnel (i.e. those not part of the research team), is allowed (up to 3 years) only when the Spanish applicant is the transnational consortium coordinator.</li> <li>*Students and fellows are not eligible.</li> <li>Prefixed bulk cost (salary + taxes + social security, etc.) per annual full-time contract.</li> <li>Technical expert, higher degree: € 29,500.00</li> <li>Technical expert, medium degree: € 24,500.00</li> <li>Technical expert, medium degree: € 24,500.00</li> <li>Technical expert, FP II: € 20,500.00</li> <li>Consumables and equipment</li> <li>Up to € 40,000.00 if the Spanish applicant is NOT the consortium coordinator.</li> <li>Travel and allowance only applies to the project's research team:</li> <li>Up to € 6,000.00 (devoted to dissemination of results, field studies and/or coordination of meetings) if the applicant is NOT the consortium coordinator.</li> <li>Up to € 6,000.00 (devoted to dissemination of results, field studies and/or coordination of meetings) if the applicant is NOT the consortium coordinator.</li> </ul>
	<ul> <li>Commissions (up to 50%).</li> <li>Subcontracting with private (Bio) companies and SMEs is permitted.</li> </ul>
	SMEs is permitted.  Overheads (ex officio): up to 21% of the project's total awarded costs.
National phase	Important: After the international evaluation has taken place, all Spanish applicants invited to the full-proposal stage, must submit the project proposal along other documents, via ISCIIIs online submission tool. For more details, please contact ISCIIIs national contact point.  Granted projects must state "Award na XX by ISCIII

	thorough AES and EC within AAL framework" on any publication arising from it even after completion of the funded period
Earliest project start date	01/01/2016
Further guidance	For more detailed information, please check Acción Estratégica en Salud: www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml